收费全文 | 176570篇 |
免费 | 10400篇 |
国内免费 | 393篇 |
耳鼻咽喉 | 2398篇 |
儿科学 | 5665篇 |
妇产科学 | 3798篇 |
基础医学 | 24574篇 |
口腔科学 | 7543篇 |
临床医学 | 12811篇 |
内科学 | 38617篇 |
皮肤病学 | 4550篇 |
神经病学 | 15039篇 |
特种医学 | 5874篇 |
外国民族医学 | 26篇 |
外科学 | 22173篇 |
综合类 | 1442篇 |
一般理论 | 61篇 |
预防医学 | 17815篇 |
眼科学 | 3350篇 |
药学 | 10956篇 |
中国医学 | 679篇 |
肿瘤学 | 9992篇 |
2023年 | 840篇 |
2022年 | 803篇 |
2021年 | 2818篇 |
2020年 | 2427篇 |
2019年 | 3408篇 |
2018年 | 4870篇 |
2017年 | 3701篇 |
2016年 | 3421篇 |
2015年 | 4041篇 |
2014年 | 5578篇 |
2013年 | 7112篇 |
2012年 | 10992篇 |
2011年 | 11491篇 |
2010年 | 5842篇 |
2009年 | 5280篇 |
2008年 | 8970篇 |
2007年 | 9598篇 |
2006年 | 8952篇 |
2005年 | 9217篇 |
2004年 | 8656篇 |
2003年 | 7935篇 |
2002年 | 6037篇 |
2001年 | 5115篇 |
2000年 | 5144篇 |
1999年 | 4488篇 |
1998年 | 1498篇 |
1997年 | 1223篇 |
1996年 | 1219篇 |
1995年 | 1158篇 |
1994年 | 1154篇 |
1993年 | 1036篇 |
1992年 | 2786篇 |
1991年 | 2705篇 |
1990年 | 2459篇 |
1989年 | 2443篇 |
1988年 | 2181篇 |
1987年 | 2039篇 |
1986年 | 1907篇 |
1985年 | 1818篇 |
1984年 | 1329篇 |
1983年 | 1058篇 |
1982年 | 626篇 |
1981年 | 566篇 |
1980年 | 539篇 |
1979年 | 986篇 |
1978年 | 660篇 |
1977年 | 520篇 |
1975年 | 585篇 |
1974年 | 591篇 |
1973年 | 611篇 |
Some 70–80% of subjects with psychotic risk syndrome (PRS) have lifetime comorbidity, with depressive disorders being the most common. A high proportion of patients with PRS present nonspecific symptoms which can be confounding factors for diagnosis. Depressive and negative symptoms may be difficult to distinguish and it is important to differentiate them. The aim of this study is to assess the presence of depressive disorder in a child and adolescent sample of PRS and to examine the presence of negative symptoms and detect possible confounding characteristics between them and depressive symptoms. This is a naturalistic multi-site study with subjects who met PRS criteria. A sample of 89 PRS adolescent patients was included. Major depressive disorder (MDD) is the most prevalent comorbid disorder (34.83%). The sample was divided into patients who met criteria for MDD (PRS-MDD, n = 31) and those who did not have this disorder (PRS-ND, n = 44). We obtained significant differences in the attenuated negative symptoms (ANS) between PRS-MDD and PRS-ND (68.18 vs. 90.32%, respectively, p = 0.021). Subjects with MDD presented a higher score in ANS and Hamilton Depression Rating Scale (HDRS). Moreover, we obtained a correlation between negative symptomatology and HDRS score with a higher score on HDRS in subjects with higher negative symptom scores (r = 0.533, p < 0.001). More research is needed to fine tune differentiation between depressive and negative symptoms and learn more about the possible impact of MDD on PRS children and adolescents.
相似文献Background
Health-related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non-Hodgkin-lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high-grade (HG)- and low-grade (LG)-NHL: the EORTC QLQ-NHL-HG29 and the EORTC QLQ-NHL-LG20 to supplement the core questionnaire (EORTC QLQ-C30).Methods
Overall, 768 patients with HG-NHL (N = 423) and LG-NHL (N = 345) from 12 countries completed the QLQ-C30, QLQ-NHL-HG29/QLQ-NHL-LG20 and a debriefing questionnaire at baseline, and a subset at follow-up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49).Results
Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ-NHL-HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/functioning [WH]), and of the 20 items of the QLQ-NHL-LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test–retest reliability, convergent validity, known-group comparisons, and RCA find satisfactory results of both measures. A total of 31%–78% of patients with HG-NHL and 22%–73% of patients with LG-NHL reported symptoms and/or worries (e.g., tingling in hands/feet, lack of energy, and worries about recurrence). Patients reporting symptoms/worries had substantially lower HRQOL compared to those without.Discussion
The use of the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision-making.Plain language summary
- The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires.
- These questionnaires measure health-related quality of life.
- The questionnaires are for patients with high-grade or low-grade non-Hodgkin lymphoma.
- They are called the EORTC QLQ-NHL-HG29 and QLQ-NHL-LG20.
- The questionnaires are now internationally validated.
- This study demonstrates that the questionnaires are reliably and valid, which are important aspects of a questionnaire.
- The questionnaires can now be used in clinical trials and practice.
- With the information gathered from the questionnaires, patients and clinicians can better evaluate treatments and discuss the best choice for a patient.